Aclaris Therapeutics Inc (NAS:ACRS)
$ 2.22 0.05 (2.3%) Market Cap: 158.39 Mil Enterprise Value: 36.85 Mil PE Ratio: 0 PB Ratio: 1.18 GF Score: 58/100

Q3 2019 Aclaris Therapeutics Inc Earnings Call Transcript

Nov 07, 2019 / 10:00PM GMT
Release Date Price: $1.69 (+4.32%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Third Quarter 2019 Aclaris Therapeutics Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Kamil Ali-Jackson. Please go ahead.

Kamil Ali;Jackson
Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing the third quarter 2019 results. For those of you who have not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com. Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Frank Ruffo, our Chief Financial Officer; Dr. David Gordon, our Chief Medical Officer; and Executive Vice President, Research and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot